Holocene

‘Difficult’ children are only slightly more likely to have insecure attachments with parents

Retrieved on: 
Wednesday, September 11, 2024

Children with difficult temperaments, including personality tendencies such as irritability and having a hard time being comforted, are only slightly more likely than other children to have insecure attachment relationships with one or both of their parents, according to our research.

Key Points: 
  • Children with difficult temperaments, including personality tendencies such as irritability and having a hard time being comforted, are only slightly more likely than other children to have insecure attachment relationships with one or both of their parents, according to our research.
  • This finding refutes the long-standing notion held by many psychologists that early attachment behaviors are mainly determined by a child’s temperament.
  • A secure attachment is likely if a caregiver is consistently available and emotionally supportive when the child is alarmed.

How we do our work

  • For this meta-analysis, we combined data collected over the past 40 years on 872 children from North American families.
  • Instead, a difficult temperament had very little to do with the number of insecure attachment relationships a child had with their parents.
  • And temperament was only slightly more difficult in infants who had insecure attachment with both parents rather than with only one or neither of the parents.

Why it matters

  • The results from our latest study suggest that even children with inborn characteristics of a difficult temperament can benefit from the advantages that come from multiple secure attachments.
  • These findings may reassure worried parents.

What still isn’t known

ParaZero Announces First Half of 2024 Financial Results

Retrieved on: 
Tuesday, September 3, 2024

TEL AVIV, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone safety systems for defense and commercial drones and urban air mobility aircraft, reported today its financial results for the six months ended June 30, 2024.

Key Points: 
  • TEL AVIV, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone safety systems for defense and commercial drones and urban air mobility aircraft, reported today its financial results for the six months ended June 30, 2024.
  • First Half 2024 Financial Highlights:
    Sales totaled to $282,693 for the six months ended June 30, 2024, compared to $344,819 for the six months ended June 30, 2023.
  • Cost of sales amounted to $209,529 for the six months ended June 30, 2024, compared to $194,104 for the six months ended June 30, 2023.
  • As of June 30, 2024, the Company’s cash and cash equivalents were $5,289,105.

Ancient viral genomes preserved in glaciers reveal the history of Earth’s climate – and how viruses adapt to climate change

Retrieved on: 
Monday, August 26, 2024

To this end, massive ice structures like glaciers serve as nature’s freezers, archiving detailed records of past climates and ecosystems – including viruses.

Key Points: 
  • To this end, massive ice structures like glaciers serve as nature’s freezers, archiving detailed records of past climates and ecosystems – including viruses.
  • We are a team of microbiologists and paleoclimatologists that studies ancient microorganisms, including viruses preserved within glacier ice.

Reading history in viral genes

  • These time horizons span three major cold-to-warm cycles, providing a unique opportunity to observe how viral communities have changed in response to different climatic conditions.
  • Only about one-fourth of the viral species we found shared species-level similarities with any of the viruses identified in nearly 1,000 metagenomes previously captured in global datasets.
  • Encoded within the viral genomes were 50 auxiliary metabolic genes related to metabolism, including the synthesis and breakdown of vitamins, amino acids and carbohydrates.
  • Some of these genes were abundant across all nine time intervals studied, suggesting that they help microbial hosts cope with the harsh conditions on glacier surfaces and thereby improve viral fitness.

Climate change over time

Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 14, 2024

The Company recorded revenue of $278,722 for the second quarter of 2024, compared to $490,110 for the comparable period in 2023.

Key Points: 
  • The Company recorded revenue of $278,722 for the second quarter of 2024, compared to $490,110 for the comparable period in 2023.
  • General and administrative expenses decreased to $2,137,189 in the second quarter of 2024 from $2,704,527 in the second quarter of 2023.
  • Operations expenses decreased to $893,391 in the second quarter of 2024 compared to $993,042 in the second quarter of 2023.
  • Sales and marketing expenses decreased to $284,421 in the second quarter of 2024 from $429,103 in the second quarter of 2023.

Beam Global Announces Record Second Quarter 2024 Operating Results

Retrieved on: 
Tuesday, August 13, 2024

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM ), (the “Company”), a provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced its second quarter results for the period ended Q2 2024.

Key Points: 
  • SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Beam Global , (Nasdaq: BEEM ), (the “Company”), a provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced its second quarter results for the period ended Q2 2024.
  • For the quarter ended June 30, 2024, our gross profit was $2.4 million, or 16% of sales.
  • Operating expenses were $7.1 million for Q2 2024 compared to $4.5 million in Q1 2024.
  • Those without internet access or unable to pre-register may call in by calling:
    Please ask to join the Beam Global call.

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Retrieved on: 
Tuesday, August 13, 2024

SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the second quarter ended June 30, 2024, and recent corporate developments.

Key Points: 
  • Matt D’Onofrio, CEO of Evoke Pharma, commented, "Exiting the second quarter of 2024 with nearly 50% growth in revenue from the previous quarter is a testament to the effectiveness of our commercial strategy.
  • For the second quarter of 2024, net product sales were approximately $2.6 million compared to $1.1 million during the second quarter of 2023, and the net loss was approximately $1.3 million, or $0.93 per share compared with $1.9 million, or $6.70 per share, for the second quarter of 2023.
  • For the second quarter of 2024, selling, general and administrative expenses were approximately $3.7 million compared to $2.8 million for the second quarter of 2023.
  • Total operating expenses for the second quarter of 2024 were approximately $3.8 million compared to $2.9 million for the same period in 2023.

Panbela Provides Business Update and Reports Q2 2024 Financial Results

Retrieved on: 
Tuesday, August 13, 2024

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024.

Key Points: 
  • MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024.
  • Q2 2024 and Recent Highlights:
    Phase 3 ASPIRE clinical trial received favorable third independent safety review: DSMB recommended continuation without modification.
  • As we move forward, Panbela remains committed to advancing our clinical programs, exploring new indications, and creating value for our stockholders.
  • Second Quarter ended June 30, 2024 Financial Results
    General and administrative expenses were approximately $1.1 million in the quarter, compared to $1.6 million in the same period last year.

BioStem Technologies Reports Record Second Quarter 2024 Revenue of $74.5 Million

Retrieved on: 
Monday, August 12, 2024

Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024

Key Points: 
  • Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024
    Financial Results Conference Call and Webcast on Monday, August 12, 2024, at 4:30 pm EDT
    POMPANO BEACH, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, reports financial results for the second quarter ended June 30, 2024.
  • Jason Matuszewski, CEO of BioStem, stated: "I am pleased to report that BioStem has achieved its second consecutive quarter of net revenue growth and profitability, with $74.5 million generated in this quarter alone.
  • The first half of 2024 has demonstrated significant revenue growth for our products, totaling $116.4 million, a considerable increase from the $1.6 million reported for the same period last year.
  • This substantial growth has also bolstered our cash position, increasing to $6.6 million for the quarter, a $6 million increase from Q1.

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, August 13, 2024

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024.
  • In June 2024, the FDA granted ADI-001 Fast Track Designation for the potential treatment of relapsed/refractory class III or class IV LN.
  • In June 2024, Adicet presented promising preclinical data supporting ADI-270’s robust anti-tumor activity in an encore poster presentation at the EHA Hybrid Congress.
  • Financial Results for Second Quarter 2024:
    Research and Development (R&D) Expenses: R&D expenses were $25.9 million for the three months ended June 30, 2024, compared to $28.4 million during the same period in 2023.

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 8, 2024

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June 30, 2024.

Key Points: 
  • ET Today
    SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the second quarter ended June 30, 2024.
  • “The second quarter of 2024 has been yet another successful period of executing our strategy to become the world’s premier endocrine company,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics.
  • Our second internally-developed candidate atumelnant* showed profoundly positive initial results in the treatment of both congenital adrenal hyperplasia and Cushing’s disease.
  • Second Quarter 2024 Financial Results:
    Research and development expenses were $58.3 million for the three months ended June 30, 2024, compared to $40.6 million for the same period in 2023.